PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Drug cocktail shows promise for Tough-to-Treat ovarian and breast cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which stops cancer cells from repairing themselves)—works better than olaparib alone for people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer…
Matched conditions: PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:51 UTC
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
Weekly chemo may improve outcomes for advanced ovarian cancer patients
Disease control OngoingThis study tested two different ways of giving the chemotherapy drug paclitaxel (either once every three weeks or once a week) along with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goa…
Matched conditions: PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Measles virus hijacks stem cells to attack returning ovarian cancer
Disease control OngoingThis study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…
Matched conditions: PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo shows promise for returning ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, peritoneal, or fallopian tube cancer that had returned after initial treatment. The goal was to see if the drugs could slow or stop tumor growth by blocking enzymes cancer cells need …
Matched conditions: PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug duo shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…
Matched conditions: PRIMARY PERITONEAL SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC